Menu
Who we are
AlgaVac’s talented team has integrated knowledge and ability from diverse fields of expertise. Together, we are breaking new ground in animal health technology. We are proud to introduce our team to you
Management
Maor Sasson, MA
Founder and CEO
Maor has a proven record of leadership in various innovative projects in governmental agencies and industries. He holds a BA in History from Ben-Gurion University, and an MA in International Relations, Strategy and Security studies from Tel-Aviv University.
Ofra Chen, PhD
Deputy CEO & CTO
Ofra is an experienced tech executive with more than 15 years of practice in the biotechnology industry, managing multidisciplinary R&D teams, intellectual property developments & business engagements with international strategic partners. Ofra holds a PhD from the Weizmann institute of science.
Ilan Gressel, MA
VP Business Development
Ilan has an MA in Financial Economics. He has proven experience in new market development and executing go-to-market strategies. Additionally, he has expertise in corporate valuations.
Zohar Rotem, C.P.A, M.B.A
CFO
Zohar has over a decade of experience in industrial companies in accounting and corporate finance roles, M&A transactions, and expertise in preparation of financial and costing statements. He has a BA degree in Business from the Ruppin Center, an M.B.A degree from the Ono Academic College (Finance and Accounting) and he is a Certified Public Accountant.
Board of directors
Daniel Gressel, PhD
Daniel Gressel, PhD
Daniel is the president and founder of Teleos Management, LLC, a global macro hedge fund based in Stamford, CT, USA, and a director at the Yankee Institute, a public policy think tank. He previously was a portfolio manager and economist at G.T. Capital Management. He holds a B.S. in Business Administration from Ohio State University, and an M.A. and Ph.D. in economics from the University of Chicago.
Maor Sasson, MA
Founder and CEO
Maor has a proven record of leadership in various innovative projects in governmental agencies and industries. He holds a BA in History from Ben-Gurion University, and an MA in International Relations, Strategy and Security studies from Tel-Aviv University.
Advisory Board
Dr. Stanley Hirsch
Dr. Stanley Hirsch is the Group CEO of FuturaGene Ltd. Prior to joining FuturaGene, Dr. Hirsch served as general manager of two diagnostics development companies and a drug development company. Dr. Hirsch served as a Chairman of a NASDAQ-traded specialty pharmaceutical company from 2017 to 2020 and as Board Director for a research products company inter alia, and has advised various venture capital funds. He currently serves on the Board of Barcode Nanotech. He received his D. Phil. from Oxford University in Cell Biology and Immunology and his B.SC and B.Sc. (Med) Honours from the University of Cape Town.